<DOC>
	<DOCNO>NCT02240433</DOCNO>
	<brief_summary>The main purpose study evaluate safety tolerability LY2157299 combine sorafenib Japanese hepatocellular carcinoma ( HCC ) participant .</brief_summary>
	<brief_title>A Study LY2157299 Participants With Unresectable Hepatocellular Cancer ( HCC )</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<criteria>Have histological evidence diagnosis HCC ( except HCC fibrolamellar mixed histology ) amenable curative surgery . Have ChildPugh Class A . Have presence measurable evaluable lesion define Response Evaluation Criteria In Solid Tumors ( RECIST ) v1.1 . A measurable evaluable lesion show demonstrable progression locoregional therapy could also include . Have receive sorafenib prior enrollment . Have resolution Grade le equal 1 National Cancer Institute ( NCI ) Common Terminology Criteria Adverse Events ( CTCAE ) version 4.03 clinically significant toxic effect prior locoregional therapy , surgery , chemoembolization , systemic chemotherapy . Have performance status less equal 1 Eastern Cooperative Oncology Group ( ECOG ) scale . Are currently enrol , discontinue within 28 day prior enrollment , clinical trial involve investigational product nonapproved use drug device ( investigational product use study ) , concurrently enrol type medical research judge scientifically medically compatible study . Have undergone major surgery within 28 day prior enrollment . Have undergone hepatic locoregional therapy ( include radiation , surgery , hepatic arterial embolization , chemoembolization , radiofrequency ablation , cryoablation , percutaneous ethanol injection , percutaneous microwave coagulation therapy ) within 28 day prior enrollment . Have moderate severe cardiac disease . Myocardial infarction within 6 month prior enrollment , unstable angina pectoris , New York Heart Association ( NYHA ) Class III/IV congestive heart failure , uncontrolled hypertension . Documented major electrocardiogram ( ECG ) abnormalities investigator 's discretion within 28 day prior enrollment . Major abnormality document echocardiography Doppler investigator 's direction within 28 day prior enrollment . Have persistently elevate brain natriuretic peptide ( BNP ) elevate troponin I within 14 day prior enrollment . Predisposing condition consistent development aneurysm ascend aorta aortic stress . Have history cardiac aortic surgery . Have undergone liver transplant . Are pregnant breastfeeding .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>